Janney Montgomery Scott
KPTI icon

Janney Montgomery Scott’s Karyopharm Therapeutics KPTI Stock Holding History

Janney Montgomery Scott’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-667
Closed -$7K – 2777
2024
Q4 		$7K Hold
667
– – ﹤0.01% 2678
2024
Q3 		$8K Hold
667
– – ﹤0.01% 2643
2024
Q2 		$9K Hold
667
– – ﹤0.01% 2589
2024
Q1 		$15K Hold
667
– – ﹤0.01% 2701
2023
Q4 		$9K Hold
667
– – ﹤0.01% 2613
2023
Q3 		$13K Hold
667
– – ﹤0.01% 2542
2023
Q2 		$18K Hold
667
– – ﹤0.01% 2617
2023
Q1 		$39K Hold
667
– – ﹤0.01% 2420
2022
Q4 		$34K Buy
+667
New +$46.2K ﹤0.01% 2525

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Janney Montgomery Scott's KPTI Position: Q1 2025 in Review

Janney Montgomery Scott sold out of Karyopharm Therapeutics (KPTI) in Q1 2025, closing a stake of 667 shares — an estimated $7K sold.

Janney Montgomery Scott first reported a position in KPTI in Q4 2022 and held it in 9 quarters. The position peaked at $39K in Q1 2023. 49 funds tracked by Wall St. Rank hold KPTI as of Q1 2025.

  • Janney Montgomery Scott reported no remaining Karyopharm Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Janney Montgomery Scott sold 667 Karyopharm Therapeutics shares in Q1 2025, an estimated $7K.
  • Janney Montgomery Scott first reported a position in Karyopharm Therapeutics in Q4 2022 and held it in 9 quarters.
  • Janney Montgomery Scott's Karyopharm Therapeutics position peaked at $39K in Q1 2023.
  • 49 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2025.

Based on Janney Montgomery Scott's 13F filing for Q1 2025, filed 17 Apr 2025.